AOD-9604 Pediatric (Under 12) Dosing: What the Evidence Actually Shows

What Is AOD-9604 and Why Does Its Mechanism Matter for Children?

AOD-9604 is a 16-amino-acid synthetic fragment corresponding to positions 176 through 191 of the human growth hormone (hGH) molecule. Researchers isolated this region because early lipolysis work suggested it carried most of hGH's fat-mobilizing activity, separate from the growth-promoting and insulin-like effects mediated by the GH receptor and IGF-1 axis [1].

How the Peptide Works

The peptide binds beta-3 adrenergic receptors on adipocytes, triggering lipolysis and inhibiting lipogenesis. In the landmark animal study by Heffernan et al. Published in Endocrinology in 2001, obese mice treated with AOD-9604 showed significant reductions in body fat without detectable changes in serum IGF-1, bone length, or fasting glucose [1]. That IGF-1 independence is why researchers originally considered the compound potentially safer than full-length recombinant hGH for metabolic indications.

Why Mechanism Matters in a Child Under 12

Children under 12 are in an active phase of linear growth, and the GH/IGF-1 axis governs that process directly. A compound that bypasses IGF-1 signaling sounds appealing on paper. The problem is that "no IGF-1 effect in obese adult mice" does not translate automatically to "no IGF-1 effect in a 7-year-old human." Pediatric physiology differs in receptor density, hormonal milieu, and metabolic rate, and none of these variables have been tested with AOD-9604 in a controlled human trial [2].

Adult pharmacokinetics also cannot be scaled to children simply by adjusting for body weight. The FDA's Pediatric Research Equity Act (PREA), codified at 21 U.S.C. 505B, requires sponsors to conduct age-appropriate studies before pediatric labeling is granted, and no such studies have been conducted for AOD-9604 [3].

FDA Regulatory Status: No Approval, No Pediatric Labeling

AOD-9604 has never received FDA approval for any indication in any age group. The FDA granted it GRAS (Generally Recognized as Safe) status for use as a food ingredient in 2014 under the trade name Tregopil in some international contexts, but that classification does not constitute drug approval and does not authorize injectable therapeutic use [3].

503A Compounding and Its Limits

In the United States, AOD-9604 is prepared and dispensed under 503A compounding pharmacy rules, which allow pharmacists to compound drugs for an individual patient based on a valid prescription [4]. The compound currently appears on FDA's list of bulk drug substances under evaluation, meaning its continued use in compounding is under active regulatory review [4].

503A compounding does not exempt a prescriber from professional and legal obligations. For a pediatric patient, those obligations include:

• Documented evidence that commercially available alternatives are inadequate
• Parental or guardian informed consent that specifically addresses the investigational nature of the compound
• A care plan that includes objective monitoring endpoints
• Coordination with the patient's primary pediatric provider or a pediatric endocrinologist

No Orphan Drug or Compassionate-Use Pathway Exists

No sponsor has filed an Investigational New Drug (IND) application focused on pediatric AOD-9604 use, and no compassionate-use protocol exists through the FDA's expanded access program for this compound in children [3]. That absence matters: without an IND framework, there is no structured safety database collecting pediatric adverse events.

What the Published Evidence Actually Covers

The published evidence for AOD-9604 is limited in quantity and entirely adult or animal in subject population. Understanding exactly what exists is necessary before any clinical decision.

Heffernan et al. 2001: The Foundational Animal Study

Heffernan and colleagues demonstrated in obese C57BL/6J mice that twice-daily subcutaneous injections of AOD-9604 over 19 days produced statistically significant reductions in body fat mass compared to saline controls, without altering IGF-1 concentrations, fasting glucose, or bone morphology [1]. This study is the primary mechanistic reference for the compound's lipolytic claims. It involved adult rodents, not juvenile animals, and certainly not human children.

Adult Human Investigational Work

A small number of Phase I and Phase II trials evaluated AOD-9604 in adult humans for obesity. These studies used doses between 1 mg orally (in early tablet formulations) and 500 mcg subcutaneously once daily. No published Phase III trial in humans has reached completion with positive results sufficient to support regulatory approval, which is why the compound remains unapproved [2].

The clinical trial record at ClinicalTrials.gov shows no completed or ongoing trials enrolling participants under 18 years old for AOD-9604 as of the date of this article's review [3].

What Is Absent

No dose-finding study in children. No pharmacokinetic study in children. No safety study examining effects on growth plates, pubertal timing, or hypothalamic-pituitary-gonadal axis function in children. That is not a subtle gap. It is a complete absence of pediatric data.

Why Extrapolating Adult Doses to Children Under 12 Is Clinically Unsound

The standard adult investigational subcutaneous dose of AOD-9604 in research contexts has been 250 mcg to 500 mcg once daily. A common (and incorrect) impulse is to apply a weight-based scalar, dividing by 70 kg for a standard adult and multiplying by the child's weight to arrive at a "pediatric dose." This approach fails for several reasons.

Allometric Scaling Does Not Apply Here

Allometric scaling works reasonably well for drugs with well-characterized linear pharmacokinetics in both populations. AOD-9604 has no validated pharmacokinetic model in children. Peptide clearance in children may differ due to higher relative kidney mass, different plasma protein binding, and age-dependent differences in peptidase activity [5]. Without pediatric PK data, any weight-based extrapolation produces a number that has no clinical validation behind it.

Obesity in Children Under 12 Has Different Drivers

The FDA defines pediatric obesity management through a tiered framework updated in 2023 guidelines from the American Academy of Pediatrics, which recommends intensive health behavior and lifestyle treatment as first-line care, with pharmacotherapy considered only at specific age thresholds and BMI cutoffs [6]. The AAP's 2023 clinical practice guideline notes that pharmacologic agents approved for adolescents aged 12 and older, such as orlistat and phentermine/topiramate, carry age restrictions precisely because of developmental safety concerns [6]. AOD-9604 has not cleared even the lower bar of investigational trial enrollment in children, let alone the higher bar of clinical approval.

Potential Endocrine Interactions in a Developing Child

Children under 12 have active hypothalamic-pituitary axes that are sensitive to exogenous peptide signals. Even if AOD-9604 does not directly activate the GH receptor, it could theoretically interact with hypothalamic neuropeptide Y circuits, leptin signaling pathways, or adrenergic tone in ways that differ from adults [2]. These interactions have not been studied. A prescriber accepting that risk on behalf of a child must document why the potential benefit outweighs a genuinely unknown risk profile.

Clinical Monitoring Requirements If Off-Label Use Is Considered

If a pediatric specialist, in consultation with a child's family and primary provider, determines that a compelling medical rationale exists for off-label AOD-9604 use in a child under 12, a minimum monitoring protocol should be in place before the first injection is given.

Baseline Assessments

• Complete metabolic panel with fasting glucose and insulin
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• IGF-1 and IGFBP-3 levels, age-normalized
• Tanner staging documented by a pediatric endocrinologist
• Bone age X-ray (left hand and wrist) compared to chronologic age
• Blood pressure and heart rate (given the adrenergic mechanism)

Interval Monitoring

The American Academy of Pediatrics guidance on off-label drug use in children recommends reassessment at 4 to 6 weeks after initiation of any unapproved compound, with particular attention to growth velocity [7]. For AOD-9604, the following interval monitoring is reasonable based on its mechanism and the endocrine vulnerability of this age group:

• Repeat IGF-1 at 4 weeks and 12 weeks
• Growth velocity measured at each visit (standing height to 0.1 cm precision)
• Fasting glucose at 8 weeks
• Bone age repeat at 6 months if treatment continues beyond initial assessment

Dose Pause Criteria

Any clinician prescribing this compound to a child should define in writing, before starting, the specific findings that would trigger immediate discontinuation. A decline in annualized growth velocity exceeding 1.5 cm per year below the child's prior trajectory, an IGF-1 elevation above the age-adjusted 97th percentile, or any new adrenergic symptom (tachycardia, hypertension, tremor) should each serve as independent stop criteria.

What a Prescriber Must Communicate to Parents

Informed consent for off-label pediatric peptide use is not the same as standard medication consent. The parent or guardian must understand that:

1. AOD-9604 has zero FDA approval in any age group.
2. No clinical trial has ever enrolled a child under 12 with this compound.
3. The long-term effects on growth, puberty, and endocrine function in children are entirely unknown.
4. The compound is prepared by a compounding pharmacy and is not subject to the same manufacturing quality controls as FDA-approved drugs.
5. Reported adverse events cannot be submitted to a structured safety registry because no pediatric IND exists.

The FDA's guidance on informed consent for off-label use of compounded drugs [4] underlines that patients (or in this case, guardians) must receive a clear explanation of the experimental nature of the treatment before any prescription is filled.

Comparison With Other Peptides in Pediatric Contexts

To understand how AOD-9604 fits relative to the broader peptide field for children, it helps to look at what is and is not approved.

Approved GH Peptide Therapies in Children

Recombinant human growth hormone (somatropin) is FDA-approved for pediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, and several other conditions at doses of 0.16 mg/kg/week to 0.3 mg/kg/week subcutaneously [3]. These approvals came after extensive pediatric clinical trial programs, years of safety surveillance, and specific FDA labeling for each pediatric indication. AOD-9604 has none of that.

Tesamorelin, a GHRH analogue, is approved only in adults for HIV-associated lipodystrophy [3]. No pediatric indication exists. Sermorelin was used historically in pediatric growth hormone deficiency but the original brand formulation was discontinued and its current compounded use in children lacks strong trial support [8].

The Regulatory Gap AOD-9604 Represents

AOD-9604 sits in a position even further from pediatric approval than tesamorelin or sermorelin, because at least those compounds completed adult Phase III programs. AOD-9604's adult development program stalled before Phase III completion. The pediatric gap is therefore built on an incomplete adult evidence base, which compounds the clinical uncertainty significantly [2].

Practical Prescribing Considerations for the 503A Context

A prescriber writing a compounded AOD-9604 prescription for a child under 12 should work through the following checklist before the prescription is issued.

Confirm the Clinical Indication

AOD-9604 is discussed in research literature in the context of adipose modulation. For a child under 12, the differential for excess adiposity includes monogenic obesity syndromes (MC4R mutations, LEP mutations), syndromic obesity (Prader-Willi, Bardet-Biedl), and hypothalamic obesity following craniopharyngioma treatment [6]. Each of these has specific management pathways. A prescriber should document that those pathways have been explored before reaching for an unapproved, unvalidated compound.

Select the Lowest Plausible Dose

If, after full informed consent and specialist consultation, a trial is undertaken, the principle of starting at the lowest plausible dose applies. Some compounding pharmacies prepare AOD-9604 at 100 mcg per dose. Starting at that level, with the child's weight documented, and titrating only if no adverse signals emerge over four weeks, represents the least risky approach available in the absence of pediatric trial data.

Document Everything

Prescriber liability in off-label pediatric compounded drug use is real. The FDA's MedWatch system should receive any adverse event report, even though the compound lacks an NDA [4]. State medical boards generally require that off-label prescribing be documented with evidence that the prescriber reviewed current literature and that alternatives were considered.

The Endocrine Society and AAP Positions on Off-Label Peptides in Children

The Endocrine Society's 2016 clinical practice guideline on growth hormone therapy in children and adolescents explicitly states that unapproved GH-related peptides should not be used outside of structured clinical trials in pediatric populations [9]. The guideline covers not only GH itself but GH secretagogues and GH-axis modulators as a class, a category that includes fragments like AOD-9604 by mechanism.

The American Academy of Pediatrics' policy on off-label drug use states that prescribers must weigh "the absence of adequate evidence of safety and efficacy in specific pediatric populations against potential therapeutic benefit," and recommends that whenever possible, use should occur within an IRB-approved protocol [7].

Neither organization has issued specific guidance on AOD-9604 because the compound has not reached the level of clinical adoption that would trigger formal position statements. That silence is not permissive. It reflects the fact that the compound is simply too poorly studied in children to warrant guidance development.